Back to top
more

Becton, Dickinson and Company (BDX)

(Delayed Data from NYSE)

$241.74 USD

241.74
1,499,503

+3.90 (1.64%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $241.86 +0.12 (0.05%) 5:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada

by Zacks Equity Research

Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

Shaun Pruitt headshot

2 Unique Dividend Aristocrats to Diversify the Portfolio

by Shaun Pruitt

Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

by Zacks Equity Research

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.

BD's (BDX) New FDA Approval to Improve Vaginitis Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

PacBio's (PACB) Latest Offering to Enhance Genome Analysis

by Zacks Equity Research

PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a concern.

PerkinElmer (PKI) Completes Divestment, New Business Name in Q2

by Zacks Equity Research

PerkinElmer (PKI) completes separation of its businesses into two entities ¿¿¿ the AES business, and the Life Sciences and Diagnostics business.

Ethan Feller headshot

3 Stocks to Buy for Consistent Dividend Growth

by Ethan Feller

Some of these companies have been around for over 100 years and have seen all imaginable economic environments

Three Reasons to Add BD (BDX) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests

by Zacks Equity Research

Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.

BDX or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. ALGN: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage

by Zacks Equity Research

Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage are included in this Analyst Blog.

Veeva Systems (VEEV) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research

Veeva Systems' (VEEV) Q4 results reflect impressive performances by both segments.

Sheraz Mian headshot

Top Analyst Reports for Schlumberger, Becton Dickinson & Marathon Petroleum

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Schlumberger Limited (SLB), Becton, Dickinson and Company (BDX) and Marathon Petroleum Corporation (MPC).

National Vision (EYE) Q4 Revenues Miss Mark, Margins Down

by Zacks Equity Research

National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.

Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls

by Zacks Equity Research

Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.

Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.

BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.

Insulet (PODD) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Inogen (INGN) Q4 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues in its domestic business-to-business sales channel.